Drug Type Antibody fusion proteins |
Synonyms anti-EGFR/anti-CDx bispecific antibody (Shenogen Pharma Group), SNG-2004 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colonic Cancer | Discovery | China | - | |
| Head and Neck Neoplasms | Discovery | China | - | |
| Lung Cancer | Discovery | China | - |






